napabucasin   Click here for help

GtoPdb Ligand ID: 11358

Synonyms: BBI-608 | BBI608
Compound class: Synthetic organic
Comment: Napabucasin (BBI608) is a small molecule naphthoquinone that blocks cancer stemness properties [3,6], It does this by targeting the signal transducer and activator of transcription 3 (STAT3) pathway [4]. Napabucasin is orally administered, and is bioactivated by the intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 (NQO1), to produce reactive oxygen species (ROS), principally NO. The high level of NO generation causes cell death, and positively correlates with the compound's anti-proliferative activity in cancer cells [1].

COVID-19: Napabucasin has been proposed as a potential repurposing candidate for the treatment of COVID-19, based on a virtual screening analysis of the interaction of existing approved and experimental compounds with the SARS-CoV-2 main protease (Mpro) [2]. Extensive in vitro and in vivo studies would be required to validate napabucasin's antiviral activity.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 64.35
Molecular weight 240.04
XLogP 1.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(=O)c1cc2c(o1)C(=O)c1c(C2=O)cccc1
Isomeric SMILES CC(=O)c1cc2c(o1)C(=O)c1c(C2=O)cccc1
InChI InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3
InChI Key DPHUWDIXHNQOSY-UHFFFAOYSA-N
References
1. Bao N, Ou J, Xu M, Guan F, Shi W, Sun J, Chen L. (2017)
Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity.
Eur J Med Chem, 137: 88-95. [PMID:28558333]
2. Chowdhury KH, Chowdhury MR, Mahmud S, Tareq AM, Hanif NB, Banu N, Reza ASMA, Emran TB, Simal-Gandara J. (2020)
Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
Biology (Basel), 10 (1). DOI: 10.3390/biology10010002 [PMID:33374717]
3. Han D, Yu T, Dong N, Wang B, Sun F, Jiang D. (2019)
Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
J Exp Clin Cancer Res, 38 (1): 289. [PMID:31277685]
4. Hubbard JM, Grothey A. (2017)
Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Drugs, 77 (10): 1091-1103. [PMID:28573435]
5. Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y et al.. (2018)
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
Lancet Gastroenterol Hepatol, 3 (4): 263-270. [PMID:29397354]
6. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB, Li CJ. (2015)
Suppression of cancer relapse and metastasis by inhibiting cancer stemness.
Proc Natl Acad Sci U S A, 112 (6): 1839-44. [PMID:25605917]
7. Löcken H, Clamor C, Müller K. (2018)
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
J Nat Prod, 81 (7): 1636-1644. [PMID:30003778]
8. Zhou Q, Peng C, Du F, Zhou L, Shi Y, Du Y, Liu D, Sun W, Zhang M, Chen G. (2018)
Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
Eur J Med Chem, 151: 39-50. [PMID:29604543]